



Consolidated Financial Results for the Second Quarter of the Fiscal Year Ending December 31, 2023 [Japanese GAAP]

August 10, 2023

Listing: Tokyo Stock Exchange

Company name: Medical Data Vision Co., Ltd.

Securities code: 3902 URL <https://www.mdv.co.jp/>

Representative: (Title) President

(Name) Hiroyuki Iwasaki

Inquiries: (Title) Executive Officer and General Manager of

(Name) Masahiro Kihara

Tel: +81-3-5283-6911

Corporate Planning Division

Scheduled date to file quarterly report: August 10, 2023

Scheduled date to commence dividend payments: -

Preparation of supplementary material on quarterly financial results : Yes

Holding of quarterly financial results briefing : Yes (for institutional investors and analysts)

(Yen amounts are rounded down to millions, unless otherwise noted)

1. Consolidated financial results for the second quarter of the fiscal year ending December 31, 2023 (from January 1, 2023 to June 30, 2023)

(1) Consolidated operating results (cumulative) (Percentages indicate year-on-year changes)

	Net sales		Operating income		Ordinary income		Net income attributable to owners of parent	
	Millions of yen	%	Millions of yen	%	Millions of yen	%	Millions of yen	%
Second quarter of FY ending December 31, 2023	3,002	5.1	719	-8.2	700	-9.7	445	-14.7
Second quarter of FY ended December 31, 2022	2,856	-	784	-	775	-	521	-

(Note) Comprehensive income Second quarter of fiscal year ending December 31, 2023 446million yen [-14.5%]

Second quarter of fiscal year ended December 31, 2022 521 million yen [-%]

	Basic earnings per share		Diluted earnings per share	
	Yen		Yen	
Second quarter of FY ending December 31, 2023	11.66		-	
Second quarter of FY ended December 31, 2022	13.64		13.63	

(Note)1. The Accounting Standard for Revenue Recognition (ASBJ Statement No. 29) and related implementation guidance have been applied from the beginning of the fiscal year ended December 2022. Consolidated earnings for the 2st quarter of the fiscal year ended December 2022, therefore, are the amount after applying such accounting standard and related implementation guidance, presenting no change from the previous corresponding period.

2. As of the end of the previous consolidated fiscal year, the provisional accounting treatment for business combinations was finalized, and the finalized provisional accounting treatment were reflected in the second quarter of the fiscal year ended December 2022.

3. Diluted earnings per share for the second quarter of the fiscal year ending December, 2023 are not presented as there are no potentially dilutive shares.

(2) Consolidated financial position

	Total assets		Net assets		Equity-to-asset ratio	
	Millions of yen		Millions of yen		%	
As of June30, 2023 (2Q FY2023)	5,586		3,826		66.8	
As of December 31, 2022 (FY2022)	4,897		3,606		71.8	

(Reference) Equity As of June 30, 2023 3,733 million yen

As of December 31, 2022 3,515 million yen

2. Cash dividends

	Annual dividends per share				
	First quarter-end	Second quarter-end	Third quarter-end	Fiscal year-end	Total
	Yen				
FY ended December 31, 2022	-	0.00	-	6.00	6.00
FY ending December 31, 2023	-	0.00	-	-	-
FY ending December 31, 2023 (forecast)	-	-	-	6.50	6.50

(Note) Revision of the latest released dividend forecast : None

3. Consolidated earnings forecasts for the fiscal year ending December 31, 2023 (from January 1, 2023 to December 31, 2023)

(Percentages indicate year-on-year changes)

	Net sales		Operating income		Ordinary income		Net income attributable to owners of parent		Basic earnings per share
	Millions of yen	%	Millions of yen	%	Millions of yen	%	Millions of yen	%	Yen
Full year	7,200	17.9	1,800	2.4	1,800	2.8	1,200	37.9	31.42

(Notes) Revision of the latest released earnings forecasts : None

* Notes

(1) Changes in significant subsidiaries during the three months ended June 30, 2023 (changes in specified subsidiaries resulting in changes in scope of consolidation) : None

Newly included: - companies (Company name) , Excluded: - companies (Company name)

(2) Application of special accounting treatment to the preparation of quarterly consolidated financial statements : None

(3) Changes in accounting policies, changes in accounting estimates, and restatement

(i) Changes in accounting policies due to revisions to accounting standards and other regulations : Yes

(ii) Changes in accounting policies other than (i) above : None

(iii) Changes in accounting estimates : None

(iv) Restatement : None

(Notes) For more details, please refer to “(3) Notes to quarterly consolidated financial statements (Change in accounting policies) in 2. Quarterly consolidated financial statements and Key notes” on page 5 of the attached materials.

(4) Number of issued shares (common shares)

(i) Total number of issued shares at the end of the period (including treasury shares)	As of June 30, 2023	40,027,526 shares	As of December 31, 2022	40,027,526 shares
(ii) Number of treasury shares at the end of the period	As of June 30, 2023	1,830,678 shares	As of December 31, 2022	1,830,678 shares
(iii) Average number of shares outstanding during the period (cumulative quarterly period)	Second quarter of FY ending December 31, 2023	38,196,848 shares	Second quarter fiscal year ended December 31, 2022	38,272,311 shares

* Quarterly financial results reports are exempt from a quarterly review conducted by certified public accountants or an audit corporation.

* Proper use of earnings forecasts, and other special matters

The forward-looking statements, including earnings forecasts, contained in this material are based on information currently available to the Group and on certain assumptions deemed to be reasonable.